menu search

GBT / See Why Jefferies Sees Massive Upside In Global Blood Therapeutics

See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145%. Read More
Posted: Oct 7 2021, 10:44
Author Name: Benzinga
Views: 111798

GBT News  

Why Global Blood Therapeutics Stock Was Trouncing the Market Today

By The Motley Fool
August 8, 2022

Why Global Blood Therapeutics Stock Was Trouncing the Market Today

The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion. more_horizontal

Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'

By Market Watch
August 4, 2022

Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'

Shares of Global Blood Therapeutics Inc. GBT, +3.04% were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is "attr more_horizontal

Global Blood Therapeutics: Powerhouse Of The Future

By Seeking Alpha
June 21, 2022

Global Blood Therapeutics: Powerhouse Of The Future

In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth du more_horizontal

Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 4, 2022

Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript

Global Blood Therapeutics, Inc. (NASDAQ:GBT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Steven Immergut – Senior more_horizontal

Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 4, 2022

Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold cl more_horizontal

Global Blood Therapeutics: Hitting A Growth Inflection

By Seeking Alpha
April 12, 2022

Global Blood Therapeutics: Hitting A Growth Inflection

Global Blood Therapeutics: Hitting A Growth Inflection more_horizontal

Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?

By Zacks Investment Research
March 25, 2022

Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? more_horizontal

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

By Seeking Alpha
March 12, 2022

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Global Blood Therapeutics: Changing My Strategy After Recent Earnings more_horizontal


Search within

Pages Search Results: